Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
PE 8: Deliverable A (Option One) PE 8: Expanding Access to Services – Hepatitis C Treatment Improvement (Option One) Quarter 1 Template Due: April 28th, 2017 Please complete the following sections describing your project plan for expanding access to services for patients with Hepatitis C (HCV). Each section is worth 0.50 point. 1. Basic Information: PIP Participant name: (if participant has more than one site) Site(s) chosen for expansion: # SFHP members assigned to above site(s): 2. Project Proposal: Was the above site offering HCV treatment or referral services prior to 1/1/17? How many patients with HCV does the above site(s) have? 3. Implementation Plan Please describe your efforts on activities 1- 2- 3 listed below in italics; these activities are required as they are best practices. Optional: add additional sub-tasks related to the operationalization of this plan at your organization. These activities may include stakeholder engagement, resource acquisition, process improvements, and/or staff training. Activity 1. Identify staff roles with respect to HCV treatment Staff Responsible Due Date 2. Develop HCV treatment workflows 3. Create HCV registry Required elements: HCV antibody status, HCV viral load confirmation, HCV genotype, payer1, payer restrictions/ requirements (e.g. formulary) 1 If patient is covered by SFHP, we encourage your collaboration with the SFHP pharmacy team. To speak with a pharmacy representative please call (415) 547-7818 ext 7085, and press option 3, or email [email protected] Optional elements may include: labs, FIB-4 and/or APRI score, cirrhosis status, particular treatment needs (e.g. unit dose, medication storage and stability), counseling on HCV treatment, counseling on HCV transmission including reinfection, HCV treatment medications, resistance testing, history of prior treatment, HIV status, HBV status, DM diagnosis, evidence of extrahepatic symptoms, other risk factors for transmission (i.e. MSM, IDU, pregnancy potential)